FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KOLTERMAN ORVILLE G 		2. Issuer Name and Ticker or Trading Symbol

AMYLIN PHARMACEUTICALS INC [ AMLN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      __ X __ Other (specify below)
SVP, Chief Medical Officer / SVP, Chief Medical Officer
(Last)          (First)          (Middle)

9360 TOWNE CENTRE DR 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/25/2012
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/25/2012     A (1)    1376.0   A $14.62   185652.9   D    
Common Stock   7/26/2012     M    13091.0   A $11.95   198743.9   D    
Common Stock   7/26/2012     F    5079.0   (2) D $30.795   193664.9   D    
Common Stock   7/26/2012     F    3739.0   (3) D $30.795   189925.9   D    
Common Stock   7/26/2012     M    7209.0   A $11.95   197134.9   D    
Common Stock   7/26/2012     F    2797.0   (2) D $30.795   194337.9   D    
Common Stock   7/26/2012     F    1777.0   (2) D $30.795   192560.9   D    
Common Stock                  12767.3   I   Indirect-401k  
Common Stock                  7974.4   I   by ESOP  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy)   $11.95   7/26/2012     M         7209.0      (4) 8/2/2012   Common Stock   7209.0   $0.0   0.0   D    
Non-Qualified Stock Option (right to buy)   $11.95   7/26/2012     M         13091.0      (4) 8/2/2012   Common Stock   13091.0   $0.0   0.0   D    

Explanation of Responses:
( 1)  Represents shares acquired through the Company's Employee Stock Purchase Plan.
( 2)  Represents the number of shares delivered to the Company to pay the exercise price of the option.
( 3)  Represents the number of shares delivered to the Company for payment of tax withholding obligations incident to the exercise of stock options.
( 4)  25% of shares vest one year from the date of grant and the remainder vest monthly over the next three years becoming fully vested four years from the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
KOLTERMAN ORVILLE G
9360 TOWNE CENTRE DR
SAN DIEGO, CA 92121

SVP, Chief Medical Officer SVP, Chief Medical Officer

Signatures
By: /s/ James R. Oehler, Attorney-in-Fact For: Orville G. Kolterman 7/26/2012
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.